Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sven Rottenberg

Showing results (1-10 of 121) with videos related to

Pageof 13
Sort By:
Trends in Molecular Medicine|May 25, 2021
Studying PAR-Dependent Chromatin Remodeling to Tackle PARPi ResistanceChristina Andronikou, Sven Rottenberg
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|February 17, 2012
Drug resistance in the mouse cancer clinicSven Rottenberg, Piet Borst
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|January 1, 2008
Modeling therapy resistance in genetically engineered mouse cancer modelsSven Rottenberg, Jos Jonkers
Genome Medicine|December 30, 2018
Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage responsePaola Francica, Sven Rottenberg
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|March 26, 2005
Cancer cell death by programmed necrosis?Piet Borst, Sven Rottenberg
Trends in Cancer|March 1, 2024
Persisting cancer cells are different from bacterial persistersMorgane Decollogny, Sven Rottenberg
Molecular Cell|February 2, 2024
DNA repair, gap suppression, or fork protection: BRCA2 needs a break!Diego Dibitetto, Sven Rottenberg
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|August 27, 2015
Minimal residual disease in cancer therapy--Small things make all the differenceSohvi Blatter, Sven Rottenberg
Breast Cancer Research : BCR|November 7, 2012
MEK inhibition as a strategy for targeting residual breast cancer cells with low DUSP4 expressionSven Rottenberg, Jos Jonkers
Veterinary Sciences|September 27, 2025
Advancing In Vitro Tools for Oncologic Research in Cats and DogsChang He, Sven Rottenberg
Pageof 13

Showing results (1-10 of 121) with videos related to

Sort By:
Pageof 13
Trends in Molecular Medicine|May 25, 2021
Studying PAR-Dependent Chromatin Remodeling to Tackle PARPi ResistanceChristina Andronikou, Sven Rottenberg
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|February 17, 2012
Drug resistance in the mouse cancer clinicSven Rottenberg, Piet Borst
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|January 1, 2008
Modeling therapy resistance in genetically engineered mouse cancer modelsSven Rottenberg, Jos Jonkers
Genome Medicine|December 30, 2018
Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage responsePaola Francica, Sven Rottenberg
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|March 26, 2005
Cancer cell death by programmed necrosis?Piet Borst, Sven Rottenberg
Trends in Cancer|March 1, 2024
Persisting cancer cells are different from bacterial persistersMorgane Decollogny, Sven Rottenberg
Molecular Cell|February 2, 2024
DNA repair, gap suppression, or fork protection: BRCA2 needs a break!Diego Dibitetto, Sven Rottenberg
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|August 27, 2015
Minimal residual disease in cancer therapy--Small things make all the differenceSohvi Blatter, Sven Rottenberg
Breast Cancer Research : BCR|November 7, 2012
MEK inhibition as a strategy for targeting residual breast cancer cells with low DUSP4 expressionSven Rottenberg, Jos Jonkers
Veterinary Sciences|September 27, 2025
Advancing In Vitro Tools for Oncologic Research in Cats and DogsChang He, Sven Rottenberg
Pageof 13